Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-cash Items (2016 - 2021)

Historic Non-cash Items for ImmunityBio (IBRX) over the last 8 years, with Q2 2021 value amounting to $19.0 million.

  • ImmunityBio's Non-cash Items fell 3736.58% to $19.0 million in Q2 2021 from the same period last year, while for Jun 2021 it was $19.0 million, marking a year-over-year decrease of 3736.58%. This contributed to the annual value of $21.9 million for FY2020, which is 28392.29% up from last year.
  • As of Q2 2021, ImmunityBio's Non-cash Items stood at $19.0 million, which was down 3736.58% from $54.3 million recorded in Q1 2021.
  • ImmunityBio's Non-cash Items' 5-year high stood at $54.3 million during Q1 2021, with a 5-year trough of $563000.0 in Q4 2018.
  • Its 5-year average for Non-cash Items is $15.8 million, with a median of $9.8 million in 2018.
  • As far as peak fluctuations go, ImmunityBio's Non-cash Items crashed by 9527.68% in 2018, and later soared by 223492.31% in 2020.
  • Quarter analysis of 5 years shows ImmunityBio's Non-cash Items stood at $11.9 million in 2017, then tumbled by 95.28% to $563000.0 in 2018, then surged by 914.21% to $5.7 million in 2019, then soared by 283.92% to $21.9 million in 2020, then fell by 13.27% to $19.0 million in 2021.
  • Its Non-cash Items was $19.0 million in Q2 2021, compared to $54.3 million in Q1 2021 and $21.9 million in Q4 2020.